Tirzepatide is usually introduced as a "dual agonist", which is accurate and tells you almost nothing. What is worth knowing about it, from the point of view of someone handling a vial, is that it is a large acylated synthetic peptide: near 4,800 daltons, built by stepwise synthesis, and carrying a fatty acid chain that makes it behave differently from an ordinary peptide during purification and analysis.

Identity on paper

Before anything else, the numbers that define the molecule:

  • CAS number: 2023788-19-2
  • Molecular formula: C225H348N48O68
  • Molecular weight: approximately 4,813 g/mol
  • PubChem CID: 156588324

Those identifiers are what a certificate of analysis should tie a batch to. A name on a label can be a marketing decision. A formula and a mass cannot.

A name is not an identifier

Over its life a single molecule collects several names. There is usually a development code assigned by whoever first made it, then an international nonproprietary name, then whatever a supplier or a catalogue chooses to call it. All of them point at the same structure and none of them is the structure.

This matters more than it sounds when you are buying material. A name can be changed by a decision. A CAS number, a molecular formula and a measured mass cannot. The useful question about a vial is what the certificate says it weighs and how pure it is. Our note on CAS numbers covers why that particular identifier is worth checking.

Why the fatty acid chain is there

Tirzepatide is not a bare peptide. A fatty diacid chain is attached to the backbone through a linker, and that modification is deliberate. Acylating a peptide with a fatty acid gives it the ability to associate reversibly with serum albumin, and peptides that bind albumin are cleared more slowly than those that do not. It is a general strategy in peptide chemistry. (Reference: Hijazi, 2021)

The practical consequence for anyone analysing the material is that the fatty chain makes the molecule considerably more hydrophobic, so it is retained longer on a reversed-phase column than its unmodified backbone would be.

Two receptors, and the incretin background

GIP and GLP-1 are incretins: signalling molecules released by the gut in response to nutrients, each acting through its own receptor and each connected to pathways involved in insulin signalling and glucose handling. The biology of the two has been reviewed extensively. (Reference: Baggio & Drucker, 2007) Most earlier compounds in this space engaged GLP-1 alone. Tirzepatide engages both receptors, which is the research question it exists to explore. For the background, see our notes on incretins and on how GLP-1 and GIP differ.

Engaging two receptors is not the same as engaging them equally

Receptor pharmacology work has characterised tirzepatide as an imbalanced and biased agonist: its activity is not evenly distributed between the two receptors, and at a given receptor it does not necessarily trigger every downstream branch in the same proportion that the native ligand does. (Reference: Willard et al., 2020) That asymmetry is the interesting part of the molecule from a laboratory standpoint, and it is why "dual agonist" says less than it appears to.

Why a 4,800 dalton peptide is hard to make well

Length is the enemy of a clean synthesis. Each coupling cycle in solid-phase synthesis that falls short of completion leaves a fraction of chains one residue behind, and those shortened chains carry on through every cycle that follows. In a long sequence there are many opportunities for that to happen, and the resulting deletion sequences differ from the target by a single residue, which makes them the hardest impurities to separate.

The acylation step adds a second thing that can go wrong: material that is otherwise correct but missing the fatty acid, or carrying it in the wrong place, is a distinct compound with a distinct mass.

Chains of this length also sit near the practical limit of building a sequence one residue at a time, which is why long syntheses are often assembled from shorter fragments joined afterwards rather than run as a single uninterrupted loop. Whichever route is used, the consequence for the buyer is the same: the purity figure is doing real work, and a batch without one is a batch you know nothing about.

What verification has to establish

For a molecule of this size, the two routine measurements answer different questions and neither is optional.

  • Purity comes from chromatography and reports what share of the detected material is the target. It is where deletion sequences show up, usually as small peaks close to the main one.
  • Identity comes from mass spectrometry. At nearly 4,813 daltons, the gap between the monoisotopic and average mass is no longer a rounding detail, so a certificate that reports an observed mass should say which convention it used.

Material arrives lyophilized, and each batch can be checked against its paperwork by batch number before the vial is opened.

Storage follows from the chemistry

Nothing about the acylation changes the basic rule for a freeze-dried peptide: the dry form is the stable one, and moisture is what degrades it. A cold vial should be allowed to reach room temperature before it is opened, so that condensation does not form inside, and the water content of the powder is one of the figures a thorough certificate reports. Our guide to storing research peptides covers the general case.

Research use only

All products sold by Codex Research, including tirzepatide, are strictly for laboratory research and development. They are not for human or animal consumption and are not intended to diagnose, treat, cure, or prevent any disease.

The compound at Codex Research

Tirzepatide (listed as GLP2-T), 20 mg per vial · batch-verified, with its certificate of analysis.

Frequently asked questions

What is tirzepatide, chemically?

A large synthetic peptide with the formula C225H348N48O68 and a molecular weight of approximately 4,813 g/mol, carrying a fatty diacid chain attached to the backbone through a linker. Its CAS number is 2023788-19-2.

Why does tirzepatide have a fatty acid attached?

Acylation with a fatty acid lets a peptide associate reversibly with serum albumin, and albumin-bound peptides are cleared more slowly. It is a general strategy in peptide chemistry. For analysis, the chain also makes the molecule more hydrophobic and therefore more strongly retained on a reversed-phase column.

Is tirzepatide a GLP-1 peptide?

It acts at the GLP-1 receptor but not only there. It engages both the GIP and the GLP-1 receptor, which is what distinguishes it from compounds targeting GLP-1 alone.

What does it mean that tirzepatide is a biased agonist?

Receptor pharmacology work has described its activity as unevenly distributed between the two receptors, and as not necessarily triggering every downstream branch in the same proportion as the native ligand would. Engaging two receptors is not the same as engaging them equally.

Why is a long peptide harder to synthesise cleanly?

Every coupling cycle that falls short leaves a fraction of chains one residue behind, and those chains continue through the remaining cycles. Long sequences give that more chances to happen, and the resulting deletion sequences differ from the target by a single residue, which makes them difficult to separate.

How is a tirzepatide batch verified?

Chromatography establishes what share of the detected material is the target, and mass spectrometry establishes that the target is the intended molecule. At this molecular weight the difference between monoisotopic and average mass is significant, so the certificate should state which one it reports.

References

Related articles